ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Patricia A. Thistlethwaite
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thistlethwaite, P. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Thistlethwaite, P. A.
Related Collections
Right arrow Molecular biology

Ann Thorac Surg 2003;75:465-466
© 2003 The Society of Thoracic Surgeons

Invited commentary

Patricia A. Thistlethwaite, MD, PhD

Division of Cardiothoracic Surgery, University of California, San Diego, 200 West Arbor Dr, MC Suite 8892, San Diego, CA 92103-8892, USA

e-mail: pthistlethwaite{at}ucsd.edu

Although cardiac surgeons encounter calcific degenerative aortic valve disease on a frequent basis, little is known about the molecular causes of this disease. The study by Dr Jian and colleagues presents convincing evidence that transforming growth factor-ß1 (TGF-ß1) may be an important piece in the puzzle of the etiology of this disease.

Clues as to the causes of calcific aortic valve degeneration are revealed by pathologic analysis of diseased cusps removed at the time of valve replacement. In normal circumstances, aortic valve leaflets are composed of three principal layers: the ventricularis at the inflow surface, the spongiosa in the center, and the fibrosa at the outflow surface. The extracellular matrix components of these layers have been well characterized: the ventricularis contains radially aligned collagen and is rich in elastin; the spongiosa is primarily composed of glycosaminoglycans with some collagen; and the fibrosa contains densely packed collagen fibers aligned in parallel with the free edge of the valve cusp [1]. In calcific degeneration, five basic processes are observed: (1) focal endothelial damage of the fibrosa or outflow tract side; (2) inflammatory cellular infiltration of damaged sites with macrophages; (3) vascular smooth muscle transformation into an osteogenic phenotype making these cells capable of initiating mineralization; (4) vascular smooth muscle cell apoptosis with vesicle formation; (5) apatite nucleation of these sites with calcification of devitalized cells [2]. Thus the calcified valve nodules we encounter as surgeons represent focal areas of cell death, petrification of cellular degradation products with calcium, and deposition of extracellular matrix proteins commonly associated with bone.

Why do apoptotic cells and cellular debris become calcified instead of resorbed? The conversion of vascular smooth muscle cells into an osteoblastic phenotype appears central to this process. Extracellular proteins common to bone have been isolated from degenerating aortic valves including, osteocalcin, osteopontin, bone morphogenetic proteins, matrix metalloproteinases 2 and 9, tenascin-C, and matrix Gla protein [35]. It is speculated that the normal "checks and balances" between these positive and negative regulators of bone formation stimulates the calcification process. A careful assessment of both transgenic and knockout mice that either overexpress or lack the ability to produce these factors will shed light on which of these are truly causal of the mineralization process.

Dr Jian and colleagues have identified high levels of TGF-ß1 in calcified valve nodules and demonstrate the TGF-ß1 stimulates aortic valve interstitial cell in culture to aggregate, induce cellular apoptosis, and calcify. These experiments suggest that this bone/smooth muscle cell factor may play a role in the cascade of cellular death and transformation. It opens the doors to testing agents which block TGF-ß production, release, and function for ability to prevent valve calcification. The molecular dissection of this surgical disease has begun.

References

  1. Paranya G., Vineberg S., Dvorin E., et al. Aortic valve endothelial cells undergo transforming growth factor-ß-mediated and non-transforming growth factor-B-mediated transdifferentiation in vitro. Am J Pathol 2001;159:1335-1343.[Abstract/Free Full Text]
  2. Farzaneh-Far A., Proudfoot D., Shanahan C., Weissberg P.L. Vascular and valvular calcification: recent advances. Heart 2001;85:13-17.[Free Full Text]
  3. O’Brien K.D., Kuusisto J., Reichenback D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995;92:2163-2168.[Abstract/Free Full Text]
  4. Jian B., Jones P.L., Li Q., Mohler E.R., Schoen F.J., Levy R.J. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001;159:321-327.[Abstract/Free Full Text]
  5. Luo G., Ducy P., McKee M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.[Medline]



This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Y. Y. Yip, J.-H. Chen, R. Zhao, and C. A. Simmons
Calcification by Valve Interstitial Cells Is Regulated by the Stiffness of the Extracellular Matrix
Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 936 - 942.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. M. Rajamannan
Calcific Aortic Stenosis: Lessons Learned From Experimental and Clinical Studies
Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 162 - 168.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Sucosky, K. Balachandran, A. Elhammali, H. Jo, and A. P. Yoganathan
Altered Shear Stress Stimulates Upregulation of Endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-{beta}1-Dependent Pathway
Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 254 - 260.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. J. Levy
Serotonin Transporter Mechanisms and Cardiac Disease
Circulation, January 3, 2006; 113(1): 2 - 4.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Patricia A. Thistlethwaite
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thistlethwaite, P. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Thistlethwaite, P. A.
Related Collections
Right arrow Molecular biology


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS